# EDGAR Filing Document

**Accession Number:** 0001560293
**File Stem:** 0001213900-25-097880
**Filing Date:** 2025-10
**Character Count:** 77052
**Document Hash:** 3b53de7adda60cbce031630d3b0f59db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-097880.hdr.sgml**: 20251010

**ACCESSION NUMBER**: 0001213900-25-097880

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 35

**FILED AS OF DATE**: 20251010

**DATE AS OF CHANGE**: 20251009

**EFFECTIVENESS DATE**: 20251010

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tenon Medical, Inc.
- **CENTRAL INDEX KEY:** 0001560293
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455574718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290808
- **FILM NUMBER:** 251386062

**BUSINESS ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032
- **BUSINESS PHONE:** (408) 649-5760

**MAIL ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032

**As filed with the Securities and Exchange Commission on October 9, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER**

**THE SECURITIES ACT OF 1933**

**TENON MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **3841** | **45-5574718** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification No.) |

---

**104 Cooper Court**

**Los Gatos, CA 95032**

**(408) 649-5760**

(Address of Principal Executive Offices)

**Tenon Medical, Inc. 2022 Equity Incentive Plan**

(Full title of the plan)

**Steven M. Foster**

**Chief Executive Officer and President**

**Tenon Medical, Inc.**

**104 Cooper Court**

**Los Gatos, CA 95032**

(Name and Address of Agent For Service)

**(408) 649-5760**

(Telephone number, Including Area Code, of Agent For Service)

***Copies of all communications, including all communications sent to the agent for service, should be sent to:***

**Ross D. Carmel, Esq.**

**Jeffrey P. Wofford, Esq.**

 **Anna Chaykina, Esq.<br> Sichenzia Ross Ference Carmel LLP<br> 1185 Avenue of the Americas, 31<sup>st</sup> Floor**

**New York, NY 10036<br> (646) 838-1310**

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.**

---

| | |
|:---|:---|
| **Large accelerated filer** ☐ | **Accelerated filer** ☐ |
| **Non-accelerated filer** ☒ | **Smaller reporting company** ☒ |
|  | **Emerging Growth Company** ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement will become effective upon filing in accordance with Rule 462(a) under the Securities Act.**

**EXPLANATORY NOTE**

**REGISTRATION OF ADDITIONAL SECURITIES** 

This Registration Statement on Form S-8 (the "**Registration Statement**") registers 1,208,882 additional shares of common stock of Tenon Medical, Inc., Delaware corporation, (the "**Registrant**") to be issued pursuant to the Registrant's Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended (the "**2022 Plan**").

Pursuant to General Instruction E of Form S-8 under the Securities Act of 1933, as amended ("**Securities Act**"), this Registration Statement consists only of those items required by General Instruction E to Form S-8. Accordingly the Registrant incorporates by reference into this Registration Statement the contents of (1) the registration statement on Form S-8 (File No. 333-268360), filed with the Securities and Exchange Commission (the "**SEC**") on November 15, 2022, relating to the registration of 29,092 shares of Registrant's common stock, par value $0.001 per share ("**Common Stock**") authorized for issuance under the 2022 Plan , and (2) the registration statement on Form S-8 (File No. 333-271778), filed with the SEC on May 9, 2023, relating to the registration of additional 5,618 shares of Common Stock authorized for issuance under the 2022 Plan, in each case, except for Items 3 and 8, which are being updated by this Registration Statement.

Since May 9, 2023, the number of shares of Common Stock reserved and available for issuance under the 2022 Plan has been increased as follows: (i) by 13,002 shares pursuant to an automatic increase under the 2022 Plan as of January 1, 2024; (ii) by 137,500 shares as approved by the stockholders holding a majority of the voting power of the Registrant as of July 23, 2024, (iii) by 13,750 shares pursuant to an automatic increase under the 2022 Plan as of January 1, 2025, and (iv) by 1,138,495 shares as approved by the stockholders holding a majority of the voting power of the Registrant as of September 18, 2025 ("**September 2025 Amendment**").

This Registration Statement provides for the registration of an additional 1,208,882 shares of Common Stock issuable under the 2022 Plan. These 1,208,882 shares represent: (i) 70,387 shares of Common Stock, that are reserved and available for issuance under the 2022 Plan and have not been registered by the Registrant pursuant to previously filed registration statements on Form S-8, and (ii) 1,138,495 shares, reserved and available for issuance under the 2022 Plan pursuant to the September 2025 Amendment.

The Common Stock share amounts stated above are presented on a post-split basis and reflect the 1-for-10 reverse stock split effected by the Registrant on November 2, 2023 and the 1-for-8 reverse stock split effected by the Registrant on September 6, 2024.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). The following documents, which are previously filed with the SEC, are incorporated into this Registration Statement by reference:

(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1560293/000101376225002734/ea0234739-10k_tenon.htm) for the year ended December 31, 2024, filed with the SEC on March 26, 2025;

(b) the Registrant's Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC on [May 13, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm) and [August 13, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025075652/ea0251411-10q_tenon.htm), respectively;

(c) the Registrant's Current Reports on Form 8-K filed with the SEC on [March 12, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025023304/ea0234065-8k_tenon.htm), [March 27, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000101376225003341/ea0235831-8k_tenon.htm), [March 28, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000101376225004228/ea0236016-8k_tenon.htm), [August 7, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025072781/ea0252007-8k_tenon.htm), and [September 23, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025090627/ea0258406-8k_tenon.htm); and

(d) The description of the Registrant's common stock, which is contained in a registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1560293/000157587222000322/cm057_8a-12b.htm) filed with the SEC on April 26, 2022 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed "filed" with the SEC.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit<br> Number** | **Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed<br> Herewith** |
| **Exhibit<br> Number** | **Description** | **Schedule<br> Form** | **File<br> Number** | **Exhibit** | **Filing Date** | **Filed<br> Herewith** |
| 4.1 | [Second Amended and Restated Certificate of Incorporation of the Registrant, filed on April 10, 2023](http://www.sec.gov/Archives/edgar/data/1560293/000157587223000672/cm307_ex3-1.htm) | S-3 | 333-271648 | 3.1 | May 4, 2023 |  |
| 4.2 | [Certificate of Correction to Second Amended and Restated Certificate of Incorporation of the Registrant, filed on October 25, 2023](ea026057901ex4-2_tenon.htm) |  |  |  |  | **X** |
| 4.3 | [Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on November 1, 2023](http://www.sec.gov/Archives/edgar/data/1560293/000121390023084331/ea187680ex3-1_tenonmed.htm) | 8-K | n/a | 3.1 | November 7, 2023 |  |
| 4.4 | [Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on September 4, 2024](ea026057901ex4-4_tenon.htm) |  |  |  |  | **X** |
| 4.5 | [Certificate of Designations, Rights and Preferences for Series A Preferred Stock of the Registrant, filed on February 20, 2024](http://www.sec.gov/Archives/edgar/data/1560293/000121390024016218/ea0200461ex10-2_tenonmed.htm) | 8-K | n/a | 10.2 | February 22, 2024 |  |
| 4.6 | [Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock, filed on September 5, 2024](ea026057901ex4-6_tenon.htm) |  |  |  |  | **X** |
| 4.7 | [Certificate of Designations, Rights and Preferences for Series B Preferred Stock, filed on September 5, 2024](ea026057901ex4-7_tenon.htm) |  |  |  |  | **X** |
| 4.8 | [Bylaws of the Registrant](http://www.sec.gov/Archives/edgar/data/1560293/000157587221000314/tm005_ex3-2.htm) | S-1/A | 333-260931 | 3.2 | April 20, 2022 |  |
| 4.9 | [Tenon Medical, Inc. 2022 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1560293/000157587222000257/cm042_ex10-30.htm) | S-1/A | 333-260931 | 10.30 | April 20, 2022 |  |
| 4.10 | [Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of September 18, 2025](ea026057901ex4-10_tenon.htm) |  |  |  |  | **X** |
| 5.1 | [Opinion of Sichenzia Ross Ference Carmel LLP](ea026057901ex5-1_tenon.htm) |  |  |  |  | **X** |
| 23.1 | [Consent of Haskell & White LLP](ea026057901ex23-1_tenon.htm) |  |  |  |  | **X** |
| 23.2 | [Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)](ea026057901ex5-1_tenon.htm) |  |  |  |  | **X** |
| 24.1 | [Power of Attorney (included in the signature pages hereto)](#p_001) |  |  |  |  | **X** |
| 107 | [Filing Fee Table](ea026057901ex-fee_tenon.htm) |  |  |  |  | **X** |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Los Gatos, State of California, on the 9<sup>th</sup> day of October 2025.

---

| | |
|:---|:---|
| **TENON MEDICAL, INC.** | **TENON MEDICAL, INC.** |
| By: | */s/ Steven M. Foster* |
| Name: | Steven M. Foster |
| Title: | Chief Executive Officer and President<br> (Principal Executive Officer) |

---

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Steven M. Foster, Kevin Williamson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her substitutes or substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Steven M. Foster* | Chief Executive Officer, and President, Director | October 9, 2025 |
| Steven M. Foster | (Principal Executive Officer) |  |
| */s/ Kevin Williamson* | Chief Financial Officer | October 9, 2025 |
| Kevin Williamson | (Chief Financial and Accounting Officer) |  |
| */s/ Richard Ferrari* | Director | October 9, 2025 |
| Richard Ferrari |  |  |
| */s/ Richard Ginn* | Chief Technology Officer and Director  | October 9, 2025 |
| Richard Ginn |  |  |
| */s/ Stephen Hochschuler, MD* | Director | October 9, 2025 |
| Stephen Hochschuler, MD |  |  |
| */s/ Ivan Howard* | Director | October 9, 2025 |
| Ivan Howard |  |  |
| */s/ Kristine Jacques* | Director | October 9, 2025 |
| Kristine Jacques |  |  |
| */s/ Robert Weigle* | Director | October 9, 2025 |
| Robert Weigle |  |  |

---

## Exhibit 4.2

**Exhibit 4.2**

![](ex4-2_001.jpg)

![](ex4-2_002.jpg)

## Exhibit 4.4

**Exhibit 4.4**

---

| |
|:---|
| **State of Delaware** |
| **Secretary of State** |
| **Division of Corporations** |
| **Delivered 12:03 PM 09/04/2024** |
| **FILED 12:03 PM 09/04/2024** |
| **SR 20243592723 - File Number 5172409** |

---

**<u>AMENDMENT TO CERTIFICATE OF INCORPORATION</u>**

**CERTIFICATE OF AMENDMENT OF<br> SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF<br> TENON MEDICAL, INC.**

**(Pursuant to Sections 242 of the General Corporation Law of the State of Delaware)**

Tenon Medical, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify:

**FIRST:** That at a meeting of the Board of Directors of Tenon Medical, Inc. resolutions were duly adopted setting forth a proposed amendments of the Second Amended and Restated Certificate of Incorporation of said corporation, as corrected (the "Certificate of Incorporation"), declaring said amendments to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

"RESOLVED, that the Certificate of Incorporation of this corporation be amended by deleting Article IV in its entirety and inserting the following:

**ARTICLE IV**

Section 1. Number of Authorized Shares.

&nbsp;&nbsp;&nbsp;&nbsp;(a) The total number of shares of stock which the Corporation
shall have the authority to issue shall be One Hundred Fifty Million (150,000,000) shares. The Corporation shall be authorized to issue
two classes of shares of stock, designated as "Common Stock" and "Preferred Stock." The Corporation shall be
authorized to issue One Hundred Thirty Million (130,000,000) shares of Common Stock, each share to have a par value of $0.001 per share,
and Twenty Million (20,000,000) shares of Preferred Stock, each share to have a par value of $0.001 per share.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The Board of Directors of the Corporation may by resolution
authorize the issuance of shares of Preferred Stock from time to time in one or more series. The Corporation may reissue shares of Preferred
Stock that are redeemed, purchased, or otherwise acquired by the Corporation unless otherwise provided by law. The Board of Directors
is hereby authorized to fix or alter the designations, powers and preferences, and relative, participating, optional or other rights,
if any, and qualifications, limitations or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted
by the Board of Directors providing for the issuance of such class or series as may be permitted by the General Corporation Law of the
State of Delaware, including, without limitation, dividend rights (and whether dividends are cumulative) conversion rights, if any, voting
rights (including the number of votes, if any, per share, as well as the number of members, if any, of the Board of Directors or the
percentage of members, if any, of the Board of Directors each class or series of Preferred Stock may be entitled to elect), rights and
terms of redemption (including sinking fund provisions, if any), redemption price and liquidation preferences of any wholly unissued
series of Preferred Stock, the number of shares constituting any such series and the designation thereof, and to increase or decrease
the number of shares of any such series subsequent to the issuance of shares of such series, but not below the number of shares of such
series then outstanding and other powers, preferences and relative, participating, optional or other special rights of each series of
Preferred Stock, and any qualifications, limitations or restrictions of such shares as are permitted by law, all as may be stated in
such resolution.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Reverse Stock Split. Effective as of 12:01 a.m. Eastern Time
on September 6, 2024 (the " <u>Effective Time</u> "), each eight (8) shares of the Corporation's Common Stock issued
and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the Corporation or
the respective holders thereof, be combined and converted into one (1) share of Common Stock without increasing or decreasing the par
value of each share of Common Stock (the " <u>Reverse Stock Split</u> "). No fractional shares of Common Stock shall be issued
as a result of the Reverse Stock Split and fractional amounts shall be rounded up to one whole share. The Reverse Stock Split shall occur
whether or not the certificates representing such shares of Common Stock are surrendered to the Corporation or its transfer agent. Each
certificate or book entry position that immediately prior to the Effective Time represented shares of Common Stock shall thereafter represent
the number of shares of Common Stock into which the shares of Common Stock represented by such certificate or book entry position has
been combined, subject to the elimination of fractional interests set forth above."

**SECOND:** That thereafter, the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a stockholders meeting at which all shares entitled to vote thereon were present and voted, approved of the Reverse Stock Split and the proposed amendment at the Special Meeting of Stockholders held on December 21, 2023.

**THIRD:** That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, said corporation has caused this certificate to be signed on September 4, 2024.

---

| | |
|:---|:---|
| By: | /s/ Steven Foster |
| Name: | Steven Foster |
| Title: | Chief Executive Officer and President |

---

## Exhibit 4.6

**Exhibit 4.6**

![](ex4-6_001.jpg)

![](ex4-6_002.jpg)

## Exhibit 4.7

**Exhibit 4.7**

![](ex4-7_001.jpg)

TENON MEDICAL, INC. CERTIFICATE OF DESIGNATIONS, RIGHTS, AND PREFERENCES OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the Delaware General Corporation Law Tenon Medical, Inc . , a Delaware corporation (the " Corporation 's, hereby certifies that the following resolution was adopted by the Board of Directors of the Corporation (the " Board of Directors ") pursuant to the authority of the Board of Directors as required by Section 151 of the Delaware General Corporation Law . WHEREAS, the Second Amended and Restated Certificate of Incorporation of the Corporation, as amended (the " Certificate of Incorporation "), provides for a class of its authorized stock known as preferred stock, comprised of 20 , 000 , 000 shares, $0 . 001 par value per share (the " Preferred Stock' 9 , issuable from time to time in one or more series ; WHEREAS, the Board of Directors is authorized by the provisions of the Certificate of Incorporation to fix the powers, designations, preferences and relative, participating, optional or other rights, if any, and the qualifications, limitations or restrictions thereof, if any, including dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences, of any series of Preferred Stock and the number of shares constituting any such series ; NOW, THEREFORE, BE IT RESOLVED, that pursuant to this authority granted to and vested in the Board of Directors in accordance with the provisions of the Certificate of Incorporation, the Board of Directors hereby adopts this Certificate of Designations, Rights, and Preferences (the " Certificate of Designation' Q for the purpose of creating a series of Preferred Stock of the Corporation designated as Series B Preferred Stock, par value $0 . 001 per share (the " Series B Preferred Stock' Q, and hereby states the designation and number of shares, and fixes the relative rights, powers and preferences, and qualifications, limitations and restrictions of the Series B Preferred Stock as follows ; 1. Designation and Amount . The shares of such series of Preferred Stock shall be designated as "Series B Preferred Stock" and the number of shares constituting such series shall be 110 , 000 shares . Each share of Series B Preferred Stock shall be identical in all respects to every other share of Series B Preferred Stock . Such number of shares of Series B Preferred Stock may from time to time be increased (but not in excess of the total number of authorized shares of preferred stock) or decreased (but not below the number of shares of Series B Preferred Stock then outstanding) by further resolution duly adopted by the Board of Directors and by the filing of a certificate pursuant to the provisions of the Delaware General Corporation Law stating that such increase or decrease, as the case may be, has been so authorized . 2. No Maturity, Sinking Fund, Mandatory Redemption Except as otherwise provided herein, the Series B Preferred Stock has no stated maturity and will not be subject to any sinking fund for the payment of the redemption price or mandatory redemption, and will remain outstanding indefinitely unless the Series B Preferred Stock is redeemed or otherwise repurchased in accordance with this Certificate of Designations . The Corporation is not required to set aside funds to redeem the Series B Preferred Stock . 3. Ranking . With respect to payment of dividends and distribution of assets upon liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the Series B Preferred Stock will rank : (i) part passu with the Corporation's Series A Preferred Stock ; (n) senior to all other classes or series of capital stock of the Corporation now existing or hereafter authorized, classified or reclassified (other than the Corporation's Series A Preferred Stock), and (n) junior to all Indebtedness of the Corporation now existing or hereafter authorized (including Indebtedness convertible into Common Stock) . 4. Dividends . No dividends shall be payable on the Series B Preferred Stock . 1

![](ex4-7_002.jpg)

2 5 . Liquidation Preference . (a) Upon any voluntary or involuntary liquidation, dissolution, or winding up of th e Corporation, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of th e Corporation (other than th e Corporation's Series A Preferred Stock, which shall receive any distributions or payments pursuant to this Section 5 on a pari passu basis with th e Series B preferred Stock), th e holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of th e assets of th e Corporation legally available for distribution to it s stockholders, a per shar e liquidation preference equal to th e greater of(x) th e aggregate of th e Stated Values of th e Series B Preferred Stock and (y) th e amount that would be paid to th e holders of th e Series B Preferred Stock (including any accrued and unpaid dividends thereon) if, prior to such voluntary or involuntary liquidation, dissolution, or winding up of th e Corporation, th e Series B Preferred Stock had been converted into shares of Common Stock pursuant to Section 9 and th e Common Stock that has accrued thereon had been issued . In th e event that, upon such voluntary or involuntary liquidation, dissolution, or winding up, th e available assets of th e Corporation are insufficient to pay th e full amount of th e liquidating distribution s on all outstanding shares of Series B Preferred Stock, then the holders of th e Serie s B Preferred Stock shall shar e ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled . Written notice of any such voluntary or involuntary liquidation, dissolution, or winding up of th e Corporation, stating th e payment date or dates when, and th e place or places where, th e amounts distributable in such circumstances shall be payable, shall be given within ten (10) days of th e date th e Board of Directors approves such action, or no later than twenty (20) days of any stockholders' meeting called to approve such action, or within twenty (20) days of the commencement of any involuntary proceeding, whichever is ear 1 ier„ to each record holder of shares of Series B Preferred Stock at the respective addresses of such holders as the same shall appear on the stock transfer records of the Corporation . After payment of the full amount of the liquidating distributions to which they are entitled, the holders of Series B Preferred Stock will have no right or claim to any of the remaining assets of the Corporation . (b) If, at any time while th e Series B Preferred Stock i s outstanding, (i) th e Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of th e Corporation with or into another entity, (ii) the Corporation, directly or indirectly, effects any sale, assignment, transfer, conveyance, or other disposition of all or substantially all of it s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer, or exchange offer (whether by th e Corporation or another person or entity) i s completed pursuant to which holders of Common Stock are permitted to sell, tender, or exchange their shares for other securities, cash, or property and has been accepted by th e holders of more than 50 % of th e outstanding Common Stock or more than 50 % of the voting power of th e common equity of th e Corporation, or (iv) th e Corporation, directly or indirectly, in one or more related transactions consummates a stock or shar e purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin - off, merger, or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50 % of th e voting power of th e Common Stock of th e Corporation (each a " Deemed Liquidation ") ; provided, however, that th e issuance of Common Stock in a financing transaction engaged in by the Corporation shall no t be a Deemed Liquidation unless it results in more than 50 % of th e voting power of Common Stock being issued to one stockholder or a number of stockholders who report on a Schedule 13 G or Schedule 13 D pursuant to Section 13 (d) of the Exchange Act that they are acting as a single group in holding th e Common Stock, then th e Corporation shall provide at least 10 days' notic e to th e holders of the Series B Preferred Stock prior to th e consummation of th e Deemed Liquidation, which shall be deemed given by the Corporation upon th e disclosure of th e potential Deemed Liquidation in any of th e Corporation's public filing s with th e SEC . If a Deemed Liquidation occurs, any holder of Series B Preferred Stock will have th e option (the " Deemed Liquidation Option' Q to receive th e liquidation preference it would have been entitled to receive under Section 5 (a) if a voluntary or involuntary liquidation, dissolution, or winding up of th e Corporation had occurred (the "Deemed Liquidation Preference Amount") ; provided, however, if th e amount payable in a Deemed Liquidation i s less than the product of (x) 110 % of th e amount set forth in clause (x) of th e definition of "Stated Value" multiplied by (y) the number of outstanding shares of Serie s B Preferred Stock, then for purposes of calculating th e Deemed Liquidation Preference Amount only, Stated Value will be calculated from issuance at th e increased rate per annum of 10 % . A holder of th e Series B Preferred Stock may elect to exercise it s Deemed Liquidation Option by providing the Corporation with written notice of such election within five (5) business days from th e consummation of th e Deemed Liquidation pursuant to Section 5 (d) . All payments in respect of a Deemed Liquidation will be paid in shares of Common Stock based on th e Conversion Price .

![](ex4-7_003.jpg)

3 (c) In determining whether a distribution (other than upon voluntary or involuntary liquidation), by dividend, redemption, or other acquisition of shares of capital stock of the Corporation or otherwise, is permitted under the Delaware General Corporation Law, amounts that would be needed, if the Corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of holders of shares of Series B Preferred Stock shall not be added to the Corporation's total liabilities (d) Holders of the Series B Preferred Stock shall send notices pursuant to Section 5 (b) to the Chief Financial Officer of the Company at 104 Cooper Ct, Los Gatos, CA 95032 . 6. Conversion at the Option of the Corporation . On any date that ten (10) of th e last fifteen (15) daily VWAPs of the Common Stock i s 250 % higher than the Conversion Price on such date, then th e Corporation has th e right, but no t the obligation, to require and cause 50 % of th e number of outstanding shares of Serie s B Preferred Stock held by each holder of Series B Preferred Stock to be converted into shares of Common Stock using th e then current Conversion Price without th e approval of any holder of Serie s B Preferred Stock (" VWAP Required Conversion' 3 . Additionally, on and after th e date on which th e Corporation receives at least $2 . 25 million in revenues in any single financial quarter, th e Corporation ha s th e right, but no t th e obligation, to require and cause 50 % of th e number of outstanding shares of Series B Preferred Stock held by each holder of Series B Preferred Stock to be converted into shares of Common Stock using th e then current Conversion Price withou t th e approval of any holder of Series B Preferred Stock (the " Revenue Required Conversion " and collectively with th e VWAP Required Conversion, the " Required Conversions' Q . If th e criteria for both Required Conversions are met, th e Corporation may exercise it s rights to require either or both Required Conversion and if th e Corporation exercises it s rights to require both Required Conversions, 100 % of th e shares of the Series B Preferred Stock will be converted into Common Stock . The conversions effected under this Section 6 will be implemented in accordance with th e provisions of Section 8 , including the Beneficial Ownership Limitations set forth therein . 7. Voting Rmhts . (a) For so long as any shares of th e Series B Preferred Stock remain issued and outstanding, each share of Series B Preferred Stock shall entitle th e holder thereof to th e right to vot e in respect of all matters concerning th e Common Stock in an amount equal to th e number of shares of Common Stock underlying a shar e of Series B Preferred Stock on an as - converted basis on th e record date for such vote ; provided, however, th e Series B Preferred Stock shall not be entitled to any additional votes resulting from a decrease in th e Conversion Price caused by th e application of Section 9 (b) . The Common Stock (and any other class or series of capital stock of th e Corporation entitled to vote generally with th e Common Stock) and th e Series B Preferred Stock shall vot e as a single class and such voting rights shall be identical in all respects . (b) As long as any shares of Series B Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, and any such act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall be null and void ab initio, and of no force or effect : (i) amend the Corporation's Certificate of Incorporation or Bylaws so as to adversely alter the rights, preferences, privileges or powers of the Series B Preferred Stock ; (ii) create any new class or series of shares part passu or senior to the Series B Preferred Stock or increase or decrease the number of authorized shares, or change the par value, of Common Stock or Preferred Stock ; (in) pay or declare any dividend on Common Stock or junior securities of the Corporation, or incur Indebtedness in any single transaction in excess of $1 million ; or (iv) redeem, purchase or otherwise acquire any share or shares of Preferred Stock or Common Stock (other than (x) the repurchase of shares of Common Stock pursuant to a written benefit plan or employment or consulting agreement, or (y) the repurchase of any equity securities in connection with the Corporation's right of first offer with respect to those securities contained in any written agreement with the Corporation) . 8 . Conversion . (a) Each share of Series B Preferred Stock shall be convertible, at any time after the date of issuance, at the option of the holder thereof (or, upon a Required Conversion, at the option of the Corporation), into that number ot shares of

![](ex4-7_004.jpg)

4 Common Stock determined by dividing th e Stated Value for such shar e of Series B Preferred Stock by th e Conversion Price . In order for th e holder of Series B Preferred Stock to convert such Series B Preferred Stock into shares of Common Stock pursuant to this Section 8 , such holder will provide th e Corporation with a completed duly executed form of conversion notice attached hereto as Exhibit A (a " Notice of Conversion ") . The date on which th e Notice of Conversion i s delivered to th e Corporation with respect to any share of Series B Preferred Stock shall be th e conversion date (the "Conversion Date") for such share of Series B Preferred Stock . (b) Notwithstanding anything herein to th e contrary, th e Corporation shall no t effect any conversion of the Series B Preferred Stock, and a holder shall no t hav e th e right (or obligation) to convert any portion of th e Series B Preferred Stock, to th e extent that, after giving effect to an attempted conversion set forth on an applicable Notice of Conversion, such holder (together with such holder's affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with th e holder's for purposes of Section 13 (d) of th e Exchange Ac t and th e applicable regulations of th e Securities Exchange Commission ("SEC' 9 , including any "group" of which th e holder i s a member) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (as defined below) ; provided, however, that, to th e extent that a Series B Preferred Stock holder's right to convert would result in such holder exceeding th e Beneficial Ownership Limitation, then such holder shall no t be entitled to convert its Series B Preferred Stock to such extent (or in th e beneficial ownership of any shares of Common Stock as a result of such conversion to such extent) and th e portion of such conversion shall be held in abeyance for th e benefit of such holder until such time, if ever, as it s right thereto would no t result in th e holder exceeding th e Beneficial Ownership Limitation . To th e extent that any Serie s B preferred Stock has no t been partially or completely converted at th e time of such conversion, such portion of th e conversion shall be held in abeyance for th e benefit of th e holder of such Series B Preferred Stock until such holders have converted such Series B Preferred Stock . For purposes of the foregoing sentence, th e number of shares of Common Stock beneficially owned by such holder and it s affiliates shall include th e number of shares of Common Stock issuable upon conversion of th e Series B Preferred Stock subject to th e Notice of Conversion with respect to which such determination i s being made, but shall exclude th e nu mber of shares of Common Stock which are issuable upon (A) conversion of th e remaining, unconverted Series B Preferred Stock beneficially owned by such holder or any of it s affiliates, and (B) exercise or conversion of th e unexercised or unconverted portion of any other securities of th e Corporation (including any warrants) beneficially owned by such holder or any of it s affiliates that are subject to a limitation on conversion or exercise similar to th e limitation contained herein . Except as set forth in th e preceding sentence, beneficial ownership shall be calculated in accordance with Section 13 (d) of th e Exchange Act and th e applicable regulations of th e SEC . In addition, for purposes hereof, "group" has th e meaning set forth in Section 13 (d) of th e Exchange Ac t and th e applicable regulations of th e SEC . For purposes of this Section 8 (b) in determining th e number of outstanding shares of Common Stock, a holder may rely on the number of outstanding shares of Common Stock as stated in th e mos t recent of th e following ; (A) th e Corporation's mos t recent periodic or annual filing with SEC, as th e case maybe, (B) a more recent public announcement by the Corporation that i s filed with th e SEC, or (C) a more recent notice by th e Corporation or th e Corporation's transfer agent to th e holder setting forth the number of shares of Common Stock then outstanding . Upon th e written request of a holder (which may be by email), th e Corporation shall, within thre e (3) Trading Days thereof, confirm in writing to such holder (which may be via email) th e number of shares of Common Stock then outstanding . In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of th e Corporation, including shares of Series B Preferred Stock, by such holder or it s affiliates since th e date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to th e holder . The " Beneficial Ownership Limitation " shall be 4 . 99 % (or 9 . 99 % if specified by th e holder) of th e number of shares of th e Common Stock outstanding immediately after giving effect to th e issuance of shares of Common Stock pursuant to such Notice of Conversion . The Corporation shall be entitled to rely on representations made to it by th e holder in any Notice of Conversion regarding it s Beneficial Ownership Limitation . (c) Mechanics of Conversion . (i) Not later than thre e (3) Trading Days after th e applicable Conversion Date , or if the holder requests th e issuance of physical certificate(s), two (2) Trading Days after receipt by th e Corporation of th e original certificate(s) representing such shares of Series B Preferred Stock being converted, duly endorsed, and th e accompanying Notice of Conversion (the " Share Delivery Date "), th e Corporation shall deliver, or cause to be delivered, to th e converting holder a book entry statement from th e Corporation's transfer agent (or if requested by th e holder, a physical certificate or certificates) representing th e number of shares (the " Conversion Shares ") being acquired upon th e conversion of shares of Series B Preferred Stock If in th e case of any Notice of Conversion such statement i s not, or if applicable,

![](ex4-7_005.jpg)

5 such certificate or certificates are not delivered to or as directed by the applicable holder by the Share Delivery Date, the applicable holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such statement or certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such holder any original Series B Preferred Stock certificate delivered to the Corporation and such holder shall promptly return to the Corporation any Common Stock any certificates representing the shares of Series B Preferred Stock unsuccessfully tendered for conversion to the Corporation . (ii) The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series B Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable upon the conversion of all outstanding shares of Series B Preferred Stock . The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, and nonassessable . (m) No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion of the Series B Preferred Stock . As to any fraction of a share which a holder would otherwise be entitled to receive upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share . (iv) The issuance of certificates for shares of the Common Stock upon conversion of the Series B Preferred Stock shall be made without charge to any holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered ho 1 de(s) of such shares of Series B Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid . (v) Upon each Conversion Date, (i) the shares of Series B Preferred Stock being converted shall be deemed converted into shares of Common Stock and (n) the holder's rights as a holder of such converted shares of Series B Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation . In all cases, the holder shall retain all of its rights and remedies for the Corporation's failure to convert Series B Preferred Stock . 9. Certain Adjustments . (a) Stock Dividends and Stock Splits . If the Corporation, at any time while the Series B Preferred Stock is outstanding ; (i) pays a stock dividend or otherwise makes a distribution that is payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, the Series B Preferred Stock), (n) subdivides outstanding shares of Common Stock into a larger number of shares, (ni) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately afier such event . Any adjustment made pursuant to this Section 9 (a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and, in the case of a subdivision, combination or re - classification, shall become effective immediately after the effective date of such subdivision, combination or re - classification . Notwithstanding the foregoing in no event may the Conversion Price be less than the par value per share of Series B Preferred Stock . (b) Pro Rata Distributions . During such time as the Series B Preferred Stock is outstanding, if the Corporation shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of

![](ex4-7_006.jpg)

6 Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement, or other similar transaction) (a " Distribution "), at any time after the issuance of the Series B Preferred Stock, then, in each such case, the holder of Series B Preferred Stock shall be entitled to participate in such Distribution to the same extent that the holder of Series B Preferred Stock would have participated therein if the holder of Series B Preferred Stock had held the number of shares of Common Stock acquirable upon complete conversion of the Series B Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution provided, however, that, to the extent that a Series B Preferred Stock holder's right to participate in any such Distribution would result in such holder exceeding the Beneficial Ownership Limitation, then such holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of such holder until such time, if ever, as its right thereto would not result in the holder exceeding the Beneficial Ownership Limitation) . To the extent that any Series B preferred Stock has not been partially or completely converted at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the holder of such Series B Preferred Stock until such holders have converted such Series B Preferred Stock . (c) Subsequent Equity Offerings . If the Corporation at any time while the Series B Preferred Stock is outstanding, shall sell, enter into an agreement to sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Conversion Price then in effect (such issuances collectively, a " Dilutive Issuance "), then simultaneously with the consummation of each Dilutive Issuance, the Conversion Price shall be reduced to equal the Weighted Average Price . Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 9 (c) in respect of an Exempt Issuance . The Corporation shall notify the holder, in writing, no later than the Trading Day following the issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 9 (c) , indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the " Dilutive Issuance Notice ") . For purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section 9 (c) . upon the occurrence of any Dilutive Issuance, the Conversion Price will be adjusted to equal the Weighted Average Price . Notwithstanding anything to the contrary contained in this Section 9 (c), no adjustments to the Conversion Price will be made for any Dilutive Issuance until after Stockholder Approval has been obtained . For purposes of clarity, with respect to Dilutive Issuances that occur prior to Stockholder Approval, the Conversion Price will be adjusted immediately after Stockholder Approval is obtained to reflect the lowest Weighted Average Price that would have resulted from the Dilutive Issuances if no Stockholder Approval requirement was contained in this Section 9 (c) . The "Weighted Average Price" for the Series B Preferred Stock on any date of determination shall be calculated as follows: CP 2 — CP' \* (A+B) / (A+C), where: CPU — New Conversion Price CP, — Conversion Price in effect immediately prior to new issue A — Number of shares of Common Stock deemed to be outstanding immediately prior to new issue (includes all shares of outstanding common stock, all shares of outstanding preferred stock on an as - converted basis and all outstanding options on an as - exercised basis) B = Aggregate consideration received by the Corporation with respect to the new issue divided by CP, C — Number of shares of stock issued in the subject transaction

![](ex4-7_007.jpg)

7 (d) Calculations . All calculations under this Section 9 shall be made to the nearest cent or the nearest 1 / 100 th of a share, as the case may be . For purposes of this Section 9 , the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding . (e) Notice to Holder . i. Adjustment to Conversion Price . Whenever the Conversion Price is adjusted pursuant to any provision of this Section 9 , the Corporation shall promptly deliver by email to the holder a notice setting forth the Conversion Price after such adjustment and any resulting adjustment to the number of Conversion Shares and setting forth a brief statement of the facts requiring such adjustment . ii. Notice to Allow Exercise by Holder . If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation, merger, statutory conversion, transfer, domestication, or continuance to which the Corporation or any Subsidiary is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Corporation shall authorize a Deemed Liquidation or the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be delivered to each holder of Series B Preferred Stock, in writing or by electronic transmission, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be enfitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange (or other applicable transaction) is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such transaction ; provided that the failure to deliver such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice . (I) Voluntary Adjustment by Corporation . Subject to the rules and regulations of the Trading Market, the Corporation may at any time while the Series B Preferred Stock is outstanding reduce the then current Conversion Price to any amount and for any period of time deemed appropriate by the Board of Directors so long as not adverse to any holder of Series B Preferred Stock whose shares are being converted to Common Stock pursuant to such holder's conversion option or a Required Conversion . 10. Record Holders . The Corporation and its transfer agent may deem and treat the record holder of any Series B Preferred Stock as the true and lawful owner thereof for all purposes, and neither the Corporation nor its transfer agent shall be affected by any notice to the contrary . 11. No Preemptive Rmhts . No holders of the Series B Preferred Stock will, as holders of Series B Preferred Stock, have any preemptive rights to purchase or subscribe for Common Stock or any other security of the Corporation . 12. Exclusion of Other Rights . The Series B Preferred Stock shall not have any preferences or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, or terms or conditions of redemption other than expressly set forth in the Certificate of Incorporation and this Certificate of Designation, as each may be amended from time to time . 13. Headings of Subdivisions . The headings of the various subdivisions hereof are for convenience of reference only and shall not affect the interpretation of any of the provisions hereof . 14. Severability of Provisions If any preferences or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, or terms or conditions of redemption of the Series B Preferred Stock set forth in

![](ex4-7_008.jpg)

8 this Certificate of Designation are invalid, unlawful, or incapable of being enforced by reason of any rule of law or public policy, all other preferences or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, or terms or conditions of redemption of Series B Preferred Stock set forth in this Certificate of Designation which can be given effect without the invalid, unlawful, or unenforceable provision thereof shall, nevertheless, remain in full force and effect and no preferences or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, or terms or conditions of redemption of the Series B Preferred Stock herein set forth shall be deemed dependent upon any other provision thereof unless so expressed therein . 15 . Definitions . As used herein the following terms shall have the following meanings : "C ommon Stock " means the Corporation's common stock, par value $0 . 001 per share . "C ommon Stock Equivalents " means any securities of the Corporation which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant, or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise enfitles the holder thereof to receive, Common Stock . "C onversion Price " means $0 . 63625 per share, subject to adjustment as set forth herein . "E xempt Issuance " means the issuance of(a) shares of Common Stock, options or restricted stock units to employees, officers, directors or eligible service providers of the Corporation pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non - employee members of the Board of Directors or amajority of the members of a committee of non - employee directors established for such purpose for services rendered to the Corporation, provided that such issuances to service providers are issued as "restricted securities" (as defined in Rule 144 under the Securities Act of 1933 , as amended), and (b) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Corporation, provided that such securities are issued as "restricted securities" (as defined in Rule 144 under the Securities Act of 1933 , as amended) . "I ndebtedness " means (a) all obligations of the Corporation or any Subsidiary for borrowed money or with respect to deposits or advances of any kind, (b) all obligations of the Corporation or any of its Subsidiaries evidenced by bonds, debentures, notes or similar instruments, (c) all letters of credit and letters of guaranty in respect of which the Corporation or any of its Subsidiaries is an account party, (d) all securitization or similar facilities of the Corporation or any of its Subsidiaries, and (e) all guarantees by the Corporation or any of its Subsidiaries of any of the foregoing . "P erson " means any individual, corporation, estate, partnership, joint venture, association, joint - stock company, limited hability company, trust, unincorporated organization or any other entity . "S tockholder Approval " means the approval from the stockholders of the Company of the terms of this Certificate of Designation . "S tated Value " means for any share of Series B Preferred Stock, an amount equal to the product of (x) $6 . 3625 multiplied by (y) the sum of 1 plus the product of (A) 0 . 06 multiplied by (B) a fraction equal to the number of days that such share of Series B Preferred Stock has been issued divided by 365 . "S ubsidiary " of any Person means any corporation, limited liability company, partnership, association, trust or other entity of which securities or other ownership interests representing more than 50 % of the ordinary voting power (or, in the case of a partnership, more than 50 % of the general partnership interests) are owned by such Person or one or more Subsidiaries of such Person or by such Person and one or more Subsidiaries of such Person . 'T rading Day " means a day on which the Common Stock is traded on a Trading Market .

![](ex4-7_009.jpg)

9 " Trading Market " means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question ; the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing) . " VWAP " means, for any date, th e price determined by th e first of th e following clauses that applies : (a) if th e Common Stock i s then listed or quoted on a Trading Market, th e daily volume weighted average price of th e Common Stock for such date (or th e nearest preceding date) on th e Trading Market on which th e Common Stock i s then listed or quoted as reported by Bloomberg (based on a Trading Day from 9 : 30 a . m . (New York City time) to 4 : 02 p . m . (New York City time)), (b) if OTCQB or OTCQX i s no t a Trading Market, th e volume weighted average price of the Common Stock for such date (or th e nearest preceding date) on OTCQ B or OTCQX as applicable, (c) if th e Common Stock i s no t then listed or quoted for trading on OTCQB or OTCQX and if prices for th e Common Stock are then reported on th e Pink Open Market (or a similar organization or agency succeeding to it s functions of reporting prices), th e most recent bid price per shar e of th e Common Stock so reported, or (d) in all other cases, th e fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by th e holders of a majority in interest of th e Serie s B Preferred Stock then outstanding and reasonably acceptable to the Corporation, th e fees and expenses of which shall be paid by th e Corporation . {Signature page follows}

![](ex4-7_010.jpg)

10 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Designation to be signed in its name and on its behalf on this 5th day of September, 2024. TENON MEDICAL, INC. By; /s/Steven Fo.‹ter Name: Steven Foster Title: Chief Executive Officer Signature Page to Certificate ofDesignation, Rights, and Preferences of Series B Preferred Stock

![](ex4-7_011.jpg)

i i EXHIBIT A NOTICE OF CONVERSION (TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B PREFERRED STOCK) The undersigned holder hereby irrevocably elects to convert the number of shares of Series B Preferred Stock indicated below, represented by stock certificate No(s) . (the " Preferred Stock Certificates"), into shares of common stock, par value $0 . 001 per share (the " Common Stock "), of Tenon Medical, Inc . , a Delaware corporation, as of the date written below . If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto . Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designations, Rights, and Preferences of Series B Preferred Stock (the " Certificate of Desmnation ' 3 filed by the Corporation on [\*], 2024 . As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned holder (together Cth such holder's affiliates, and any other person or entity whose beneficial ownership of Common Stock would be aggregated with the holder's for purposes of Section 13 (d) of the Exchange Act and the applicable regulations of the SEC, including any "group" of which the holder is a member), including the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock subject to this Notice ot Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Preferred Stock beneficially owned by such holder or any of its affiliates, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such holder or any of its Affiliates that are subject to a limitation on conversion of the Certificate of Designation, is no more than 4 . 99 % (or 9 . 99 % if specified by the holder) . For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13 (d) of the Exchange Act and the applicable regulations of the SEC . In addition, for purposes hereof, "group" has the meaning set forth in Section 13 (d) of the Exchange Act and the applicable regulations of the SEC . Conversion calculations ; Date to Effect Conversion; Number of shares of Series B Preferred Stock owned prior to Conversion: Number of shares of Series B Preferred Stock to be Converted: Number of shares of Common Stock to be Issued: Address for delivery of physical certificates:

## Exhibit 4.10

**Exhibit 4.10**

**AMENDMENT TO TENON MEDICAL, INC. 2022 EQUITY INCENTIVE PLAN**

September 18, 2025

Subject to the approval of the stockholders (the "<u>Stockholder Approval</u>") of Tenon Medical, Inc., a Delaware corporation (the "<u>Company</u>"), at the Company's 2025 Annual Meeting of Stockholders, the Tenon Medical, Inc. 2022 Equity Incentive Plan (the "<u>2022 Plan</u>") is hereby amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Section 3</u>. Sections 3.1 and 3.2 of the 2022 Plan are hereby amended and restated in its entirety as follows:

"3.1 **Stock Subject to the Plan**. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15 of the Plan and the automatic increase set forth in Section 3.2 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan will be equal to 1,328,365 Shares. In addition, Shares may become available for issuance under Section 3.2 of the Plan. The Shares may be authorized but unissued, or reacquired Common Stock.

"3.2 **Automatic Share Reserve Increase**. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15, the number of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2026 Fiscal Year, in an amount equal to either, as determined in the sole discretion of the Administrator (x) the greater of (A) 4% of the total number of shares of common stock outstanding on the last day of the prior fiscal year or (B) a number of shares that, when added to the number of shares reserved under the Plan on the last day of the prior fiscal year will cause the number of shares reserved under the Plan to equal 15% of the total shares of common stock outstanding on the last day of the prior fiscal year, or (y) a lesser number than obtained from the application of clause (x) above, as determined by the Administrator no later than the last day of the immediately preceding Fiscal Year."

Except as expressly amended hereby, the terms of the 2022 Plan shall be and remain unchanged and the 2022 Plan as amended hereby shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has caused this Amendment to be executed by its duly authorized representative on the day and year first above written.

---

| | |
|:---|:---|
| TENON MEDICAL, INC. | TENON MEDICAL, INC. |
| By: | */s/ Steven Foster* |
| Name: | Steven Foster |
| Title: | Chief Executive Officer and President |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

October 9, 2025

Tenon Medical, Inc.

104 Cooper Ct.

Los Gatos, CA 95032

RE: Tenon Medical, Inc. <br>Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Tenon Medical, Inc., a Delaware corporation (the "***Company***"), in connection with the Registration Statement on Form S-8 (as amended, the "***Registration Statement***"), filed by the Company with the Securities and Exchange Commission (the "***Commission***") pursuant to the Securities Act of 1933, as amended (the "***Securities Act***") in connection with the offer and sale by the Company of an additional 1,208,882 shares of common stock, par value $0.001 per share (the "***Shares***"), issuable in connection with the Company's Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended ("***Plan***").

In connection with our opinion expressed below we have examined originals or copies of the Company's Second Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of the State of Delaware (the "***Certificate of Incorporation***") and the Company's Bylaws (the "***Bylaws***" and, together with the Certificate of Incorporation, the "***Charter Documents***"), the Registration Statement, together with the exhibits filed as a part thereof and all other documents incorporated therein by reference, the registration statements incorporated by reference in the Registration Statement, the prospectus relating the Plan, certain corporate proceedings of the Company's board of directors or a committee or committees of the Board relating to the Registration Statement, and such other agreements, documents, certificates and statements of the Company, and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary.

We have assumed, and express no opinion as to, the genuineness of all signatures on documents submitted to us, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the absence of any termination, modification, waiver or amendment to any document reviewed by us, the absence of any other extrinsic agreements or documents that might change or affect the interpretation or terms of documents we have reviewed, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof.

Our opinion is expressed only with respect to the Delaware General Corporation Law (the "***DGCL***"). We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable.

Based upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that the Shares have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and when the Shares are issued to the eligible individuals in accordance with the terms and conditions of the Plan and the applicable award agreement for consideration in an amount at least equal to the par value of such Shares, the Shares will be validly issued, fully paid and nonassessable.

We assume no obligation to update or supplement any of our opinions to reflect any changes of law or fact that may occur. We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving our consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| */s/ Sichenzia Ross Ference Carmel LLP* |
| Sichenzia Ross Ference Carmel LLP |

---

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Tenon Medical, Inc. (the "Company") of our report dated March 26, 2025, relating to our audits of the Company's consolidated financial statements as of December 31, 2024 and 2023, and for each of the years then ended, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.

---

| |
|:---|
| */s/ Haskell & White LLP* |
| HASKELL & WHITE LLP |

---

Irvine, California

October 9, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**TENON MEDICAL, INC.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.001 each, to be issued pursuant to the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended | (1) | Other | 1208882 | $1.19 | $1438569.58 | 0.0001381 | $198.67 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $1438569.58 |  | 198.67 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $198.67 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) This Registration Statement on Form S-8 (this "Registration Statement") covers additional shares of Common Stock, par value $0.001 per share ("Common Stock"), of Tenon Medical, Inc. (the "Company" or "Registrant") (i) authorized for issuance under the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended on September 18, 2025 (the "2022 Plan") and (ii) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), any additional shares of Common Stock that may become issuable under the 2022 Plan by reason of any stock split, stock dividend or similar transaction involving the Common Stock. Proposed maximum offering price per share was estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) promulgated under the Securities Act. The proposed maximum offering price per share and the maximum aggregate offering price are based upon $1.19 per share, which is the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Capital Market on October 6, 2025. Maximum aggregate offering price was rounded up to the nearest cent.